DK2707391T3 - Antistoffer mod her3 - Google Patents

Antistoffer mod her3 Download PDF

Info

Publication number
DK2707391T3
DK2707391T3 DK12719763.0T DK12719763T DK2707391T3 DK 2707391 T3 DK2707391 T3 DK 2707391T3 DK 12719763 T DK12719763 T DK 12719763T DK 2707391 T3 DK2707391 T3 DK 2707391T3
Authority
DK
Denmark
Prior art keywords
antibody
her3
seq
ser
gly
Prior art date
Application number
DK12719763.0T
Other languages
English (en)
Inventor
Abdelhakim Kharrat
Olivier Dubreuil
Yassamine Lazrek
Philippe Mondon
Khalil Bouayadi
Thierry Chardes
Andre Pelegrin
Christel Larbouret
Nadege A Gaborit
Original Assignee
Gamamabs Pharma
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamamabs Pharma, Inst Nat Sante Rech Med filed Critical Gamamabs Pharma
Application granted granted Critical
Publication of DK2707391T3 publication Critical patent/DK2707391T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (9)

1. Anti-HER3-antistof, som omfatter: - en tung kæde, hvor det variable domæne omfatter SEQ ID NO: 1 for H-CDR1, SEQ ID NO: 2 for H-CDR2 og SEQ ID NO: 3 for H- CDR3; og - en let kæde, hvor det variable domæne omfatter SEQ ID NO: 4 for L-CDR1, SEQ ID NO: 5 for L-CDR2 og SEQ ID NO: 6 for L- CDR3 .
2. Antistof ifølge krav 1, hvor det variable domæne af den tunge kæde har aminosyresekvensen ifølge SEQ ID NO: 7.
3. Antistof ifølge et hvilket som helst af kravene 1 eller 2, hvor det variable domæne af den lette kæde har aminosyresekvensen ifølge SEQ ID NO: 8.
4. Antistof ifølge et hvilket som helst af kravene 1-3, hvor antistoffet er valgt fra gruppen bestående af et antistof, som omfatter det variable domæne af en tung kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 7, og det variable domæne af en let kæde, hvilket variable domæne har aminosyresekvensen ifølge SEQ ID NO: 8.
5. Antistof ifølge et hvilket som helst af kravene 1-4, hvor antistoffet er et humant antistof.
6. Antistof ifølge et hvilket som helst af kravene 1-5, hvor antistoffet er et antistoffragment valgt fra gruppen bestående af Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2 og diabodies.
7. Farmaceutisk sammensætning, som omfatter et antistof ifølge et hvilket som helst af kravene 1-6 og en farmaceutisk acceptabel bærer.
8. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse som lægemiddel.
9. Antistof ifølge et hvilket som helst af kravene 1-6 til anvendelse ved behandling af cancer.
DK12719763.0T 2011-05-13 2012-05-11 Antistoffer mod her3 DK2707391T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305583 2011-05-13
PCT/EP2012/058769 WO2012156309A1 (en) 2011-05-13 2012-05-11 Antibodies against her3

Publications (1)

Publication Number Publication Date
DK2707391T3 true DK2707391T3 (da) 2018-02-05

Family

ID=46046250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12719763.0T DK2707391T3 (da) 2011-05-13 2012-05-11 Antistoffer mod her3

Country Status (8)

Country Link
US (1) US9346883B2 (da)
EP (1) EP2707391B1 (da)
DK (1) DK2707391T3 (da)
ES (1) ES2657862T3 (da)
NO (1) NO2707391T3 (da)
PL (1) PL2707391T3 (da)
PT (1) PT2707391T (da)
WO (1) WO2012156309A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
TW201331225A (zh) * 2011-12-05 2013-08-01 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
CN106459212B (zh) * 2014-02-28 2021-07-13 美勒斯公司 结合erbb-2和erbb-3的抗体
HUE055222T2 (hu) 2015-10-23 2021-11-29 Merus Nv Megkötõ molekulák, amelyek gátolják a rák növekedését
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
KR20200031571A (ko) * 2017-05-29 2020-03-24 가마맵스 파마 암 연관 면역억제의 억제제
CN111094351A (zh) 2017-08-09 2020-05-01 美勒斯公司 结合EGFR和cMET的抗体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2339013B1 (en) 2000-06-28 2014-07-02 GlycoFi, Inc. Methods for producing modified glycoproteins
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PT2716301T (pt) 2007-02-16 2017-07-04 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants

Also Published As

Publication number Publication date
PT2707391T (pt) 2018-02-06
EP2707391A1 (en) 2014-03-19
US20140141019A1 (en) 2014-05-22
EP2707391B1 (en) 2017-11-08
US9346883B2 (en) 2016-05-24
ES2657862T3 (es) 2018-03-07
NO2707391T3 (da) 2018-04-07
PL2707391T3 (pl) 2018-04-30
WO2012156309A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
DK2707391T3 (da) Antistoffer mod her3
JP6513728B2 (ja) Ｈｅｒ３に特異的な結合分子及びそれらの使用
CN113347994B (zh) 使用her3抗原结合分子治疗和预防癌症
JP6120833B2 (ja) 抗Ａｘｌ抗体及びその使用
JP6033293B2 (ja) 抗Ａｘｌ抗体及びその使用
JP2022071071A (ja) ＥｒｂＢ－２およびＥｒｂＢ－３に結合する抗体
KR20210109520A (ko) 항체 및 이의 용도
EP3116911B1 (en) Anti-mcam (cd146, muc16) antibodies and associated methods of use
CN112513095B (zh) Her3抗原结合分子
KR20170070076A (ko) 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
TW200848428A (en) Novel antibodies
WO2015048008A2 (en) Binding molecules specific for her3 and uses thereof
JP6449876B2 (ja) ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
EP3353205A1 (en) Anti-mullerian hormone (amh) neutralizing antibodies and uses thereof
EP2985292A1 (en) Epidermal growth factor receptor antibody
EP3183342B1 (en) Method for prophylaxis and/or treatment of erbb1 positive cancers
WO2017072150A1 (en) Anti-nrg1 (heregulin) antibodies and uses thereof
JP2022500072A (ja) Ｎｔｓｒ１に特異的な抗体およびその使用
WO2023031435A9 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
NZ625046B2 (en) Binding molecules specific for her3 and uses thereof